Editorially reviewed by Dr Fatimah Khan, registered with the Pakistan Medical and Dental Council (PMDC no. 104595-P). Editorial medical reviewer; does not prescribe or review patient assessments.
Review details
Review recorded:
Review scope: This article edition.
Editorial reviewer for Prescrivia. Editorial review does not establish participation in patient consultations.
Clinical review does not replace individual medical advice. Prescrivia is a technology intermediary; independent doctors make clinical decisions.
Legal review: Qualified review pending.
Language review: Qualified review pending.
Source and review
Source published:
Attributed source update:
Text edited:
Editorial role: Editorial team. This description does not establish an individual credential or clinical review of this edition.
Read our editorial policy and corrections. Edit dates and source descriptions do not establish qualified review.
How is Peyronie's disease treated?
Treatment depends on penile curvature, pain, erection difficulties, the effect on sexual activity and whether symptoms are changing or stable. A urologist's assessment is more useful than choosing a treatment from a general list.
Peyronie's disease involves scar tissue that can cause a bend during an erection. Not every curve requires intervention. A new bend, a lump, painful erections or difficulty with sex should be discussed with a clinician.
Why examination matters
Diagnosis commonly involves examination and questions about the history and symptoms; imaging may sometimes be used. An online description or photograph cannot reliably replace an examination or specialist assessment of the plaque and deformity.
Bring a history of when symptoms began, whether the curve is changing, pain and erectile function. Ask the clinician how any photographs should be provided securely if they are requested.
An acute injury with severe pain or sudden swelling needs urgent assessment rather than waiting for a routine Peyronie's consultation.
What happened to Xiapex?
Xiapex contained collagenase and had an EU authorisation that included selected Peyronie's disease cases. EMA records that the marketing-authorisation holder requested withdrawal for commercial reasons. The European Commission decision was issued on 5 December 2019 and took effect on 1 March 2020.
This is a specific historical authorisation event. It does not establish that there is no licensed treatment anywhere in Europe today, nor that a medicine authorised in another country is locally obtainable or suitable.
Any proposed injection treatment needs the exact local product status, indication and specialist expertise checked at the time of care.
What options may be discussed?
NHS guidance describes options including observation for mild disease, medicines for relevant symptoms or erectile difficulties, specialist devices and surgery. The choice depends on the individual's findings.
Devices may require use over months and are not a guaranteed way to straighten the penis. Do not begin traction or another device simply because a general guide mentions it; ask about suitability, training, discomfort and follow-up.
Surgery may be considered when symptoms substantially affect sexual activity. Discuss the expected benefit and possible effects on length, sensation and erectile function. It is not a promise to restore the penis to its previous shape.
A medicine for erectile dysfunction addresses erection difficulties, not necessarily the curvature itself.
Questions for the specialist
Ask whether symptoms are still changing, what benefit each option can realistically offer, what evidence supports it, and what risks or follow-up are involved. Ask whether observation is reasonable before committing to an intervention.
This guide does not endorse an injection, supplement, device or procedure, and it makes no Europe-wide claim about absence of licensed medicines. A qualified urologist should review the current local options.
Information and clinical decisions
This guide provides general information, not a diagnosis or personal treatment plan. Any clinical assessment and prescribing decision rests with an independent clinician. Prescrivia is a technology intermediary, not a medical provider or pharmacy; it does not prescribe, sell or dispense medicines. Assessment does not guarantee a prescription, medicine availability or a health outcome.
Further reading: treatment information.
Read about online consultations and their limits. Service information must not delay urgent local care.
Sources
- NHS: Peyronie's disease — Symptoms, examination-based diagnosis and individualised treatment options including devices and surgery.
- EMA: Xiapex authorisation history — Commercial withdrawal request and the specific EU authorisation history.
- EMA public statement: Xiapex withdrawal — Decision dated 5 December 2019, effective 1 March 2020; not a current Europe-wide treatment inventory.
See the current clinical, legal and language review statuses for this edition. Source checks are editorial work, not approval.